AxoGen, Inc. (NASDAQ:AXGN) Ratings Summary as of Apr 20, 2018

April 20, 2018 - By Georgina Andrews

AxoGen, Inc. (NASDAQ:AXGN) Corporate Logo

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

A total of 7 analysts rate AxoGen (NASDAQ:AXGN) as follows: 7 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:AXGN) has 10 ratings reports on Apr 20, 2018 according to StockzIntelligence. The company rating was maintained by Cantor Fitzgerald on Wednesday, February 28. On Tuesday, November 21 the stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Outperform” rating by Leerink Swann. In Friday, March 2 report Lake Street maintained it with “Buy” rating and $38.0 target. On Monday, January 8 the stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given by Cantor Fitzgerald. On Thursday, March 1 JMP Securities maintained the shares of AXGN in report with “Market Outperform” rating. On Tuesday, November 21 the rating was maintained by Wedbush with “Buy”. On Thursday, November 2 Leerink Swann maintained AxoGen, Inc. (NASDAQ:AXGN) with “Outperform” rating. Listed here are AxoGen, Inc. (NASDAQ:AXGN) PTs and latest ratings.

02/03/2018 Broker: Lake Street Rating: Buy New Target: $38.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $37.0 Maintain
01/03/2018 Broker: JMP Securities Rating: Market Outperform Old Target: $27 New Target: $34 Maintain
05/02/2018 Broker: William Blair Rating: Outperform Initiates Coverage On
08/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $37.0 Maintain
30/11/2017 Broker: Jefferies Rating: Buy New Target: $35 Initiates Coverage On
21/11/2017 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $26 New Target: $30 Maintain
21/11/2017 Broker: Lake Street Rating: Buy New Target: $26.0
21/11/2017 Broker: Wedbush Rating: Buy New Target: $27.0 Maintain
02/11/2017 Broker: Leerink Swann Rating: Outperform Old Target: $23 New Target: $26 Maintain

The stock decreased 0.50% or $0.2 during the last trading session, touching $40.05.AxoGen, Inc. has volume of 9,300 shares. Since April 20, 2017 AXGN has risen 293.56% and is uptrending. AXGN outperformed the S&P 500 by 282.01%.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries.The firm is worth $1.38 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.Currently it has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.